Eli Lilly reports major weight loss for experimental obesity drug
The company says its investigational candidate produced substantial weight reduction, though the report gives no trial details, dose levels or safety data.
MH
By Maren Holt · Senior Reporter, GLP-1
Oct 14 11:21 ETSource: BusinessWorld Online
The wire
- 01BusinessWorld reports Eli Lilly announced major weight-loss results for an experimental obesity drug.
- 02Incretin pipeline readouts from Lilly shape prescribing expectations, supply planning and compounding demand across telehealth and clinic operators.
- 03Endpoint figures, dosing, trial size and safety findings are not detailed in the report, so readers should wait for the full data presentation.
From the source
Read at bworldonline.comeli lilly reports experimental drug shows major weight loss results
